Estado regulatorio: Compuesto en fase de desarrollo; restringido por patente, uso solo para I+D/presentación regulatoria
IUPAC Name: [2-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]-3-pyridinyl]methyl 2-(methylamino)acetate;hydrogen sulfate
EC Number: 619-052-6
Molecular Weight: 814.8
Chemical Formula: C₃₅H₃₆F₂N₈O₉S₂
CAS Number: 946075-13-4
Pureza: > 99.5% (chemical purity)
Aplicación: Tratamiento antifúngico (aspergilosis, mucormicosis)
Tipo de formulación: Forma polimórfica amorfa
Status: Pipeline
Therapeutic cat.: Fungal
Polymorphic form: Amorphous

Otra información

Descripción adicional:

Established in 1935 and based in the Greater Poland Voivodeship, Polpharma is a manufacturer and service provider of active pharmaceutical ingredients spanning prophylactic biological products, central nervous system drugs, cardiovascular system drugs and related APIs, offering CDMO contract manufacturing to markets across North America, Latin America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa. Drawing on 75 years of experience in the API business, Polpharma API covers the full value chain from R&D through production and supply chain management to project management, operating from a European base with R&D and two manufacturing plants, and specializes in high-potency APIs (OEB 5&6), high-potency ADC payloads, advanced linker technologies, customizable ADC development solutions, cryogenic reactions and oligonucleotides. The company is recognized for international certification, an experienced R&D team, strong reputation, high-quality service and a genuinely global market presence.